Organ systems

Glucose Health, Inc. Amazon Sales for June Increase 1,284% YOY

Retrieved on: 
Wednesday, July 8, 2020
Organ systems, Publishing, Diabetes, 3D publishing, Amazon, Companies

GLUCODOWN is great-tasting and nutritious and has earned 4 or 4 star ratings on Amazon for all flavors.

Key Points: 
  • GLUCODOWN is great-tasting and nutritious and has earned 4 or 4 star ratings on Amazon for all flavors.
  • With more than 7,000 containers of GLUCODOWN sold at Amazon in the 2nd quarter, Amazon is sold out of all GLUCODOWN inventory entirely as of today July 8, 2020.
  • The new ad can be viewed at http://www.glucosehealthinc.com/tv-commercials
    Manufactured by Glucose Health, Inc., GLUCODOWN is formulated for the diabetic/adult nutrition retail category.
  • 1 National Diabetes Statistics Review, 2020; Centers for Disease Control and Prevention, Department of Health and Human Services.

BrainStorm Hosting KOL Webinar to Discuss NurOwn® Phase 2 Alzheimer's Disease Program

Retrieved on: 
Wednesday, July 8, 2020
Organ systems, Biology, Multiple sclerosis, Psychiatry, Abnormal psychology, Alzheimer's disease, Dementia, RTT, Magnetic resonance imaging, Magnetic resonance imaging

The Company recently announced that it is expanding its clinical pipeline to develop NurOwn and begin a Phase 2 study in AD.

Key Points: 
  • The Company recently announced that it is expanding its clinical pipeline to develop NurOwn and begin a Phase 2 study in AD.
  • The presentation will be followed by a question-and-answer session with Professors Scheltens and Dubois and with BrainStorm management.
  • degree (1984) and his Ph.D. in Magnetic Resonance Imaging in Alzheimer's Disease (1993) from VU University in Amsterdam.
  • BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS).

Team PH to Announce 2020 Pulmonary Hypertension Research Award Winner

Retrieved on: 
Tuesday, July 7, 2020
Hypertension, Pulmonary hypertension, Branches of biology, Organ systems, Medicine

BELOIT, Wis., July 7, 2020 /PRNewswire-PRWeb/ -- Nonprofit Team PHenomenal Hope (Team PH) will announce the 2020 winner of the PHenomenal Impact Fund for Global PH Research Award at its first ever virtual research town hall on Saturday, July 11 at noon EST.

Key Points: 
  • BELOIT, Wis., July 7, 2020 /PRNewswire-PRWeb/ -- Nonprofit Team PHenomenal Hope (Team PH) will announce the 2020 winner of the PHenomenal Impact Fund for Global PH Research Award at its first ever virtual research town hall on Saturday, July 11 at noon EST.
  • In this virtual town hall, Team PH along with clinical experts will showcase the latest research in the area of pulmonary hypertension (PH), in focused talks geared toward the community, and announce the 2020 research award.
  • The organization will also use this time to announce the researcher who will receive a $50,000 research award to further their explorations into pulmonary hypertension.
  • Team PH founder and president Patricia George shares,"This is a day to celebrate pulmonary hypertension research with Team PHenomenal Hope!

Open Source Imaging Consortium (OSIC) Launches $55,000 AI Competition to Help Pulmonary Fibrosis Patients

Retrieved on: 
Tuesday, July 7, 2020
Pulmonary fibrosis, RTT, Organ systems, Anatomy, Torso, Usual interstitial pneumonia

HOLLAND, Mich., July 7, 2020 /PRNewswire/ -- The Open Source Imaging Consortium (OSIC) announced today the launch of the $55,000 OSIC Pulmonary Fibrosis Progression , an AI-focused challenge to predict lung function decline in people living with pulmonary fibrosis.

Key Points: 
  • HOLLAND, Mich., July 7, 2020 /PRNewswire/ -- The Open Source Imaging Consortium (OSIC) announced today the launch of the $55,000 OSIC Pulmonary Fibrosis Progression , an AI-focused challenge to predict lung function decline in people living with pulmonary fibrosis.
  • The competition is administered by Kaggle , the world's largest data science community platform, and runs through October 6, 2020.
  • Its mission is to bring together radiologists, clinicians and computational scientists from around the world to improve imaging-based approaches to diagnosis, prognosis and therapy.
  • For more information on OSIC or the Pulmonary Fibrosis Progression challenge, please visit www.OSICILD.org .

Multiple System Atrophy Coalition Reports Record-Breaking Financial Growth

Retrieved on: 
Tuesday, July 7, 2020
Neurological disorders, Organ systems, Multiple system atrophy, Gross pathology, Atrophy, MSA, Coalition

CHARLOTTE, N.C., July 7, 2020 /PRNewswire-PRWeb/ -- The Multiple System Atrophy Coalition (MSA Coalition), the leading nonprofit funder of global MSA research, today announced the successful completion of its 2019 independent financial audit and the filing of its Form 990, reporting total revenue of $4.2 million.

Key Points: 
  • CHARLOTTE, N.C., July 7, 2020 /PRNewswire-PRWeb/ -- The Multiple System Atrophy Coalition (MSA Coalition), the leading nonprofit funder of global MSA research, today announced the successful completion of its 2019 independent financial audit and the filing of its Form 990, reporting total revenue of $4.2 million.
  • Overall, the Multiple System Atrophy Coalition ended the year with net assets of $5.4 million, of which $3.3 million is restricted, primarily to research.
  • The MSA Coalition will continue to rely on generous contributions and fundraisers in order to maintain the momentum towards improving quality of life and building hope for those impacted by multiple system atrophy.
  • The Multiple System Atrophy (MSA) Coalition is a positive beacon of hope standing up to a little-known, rare, insidious disorder.

Kerahealth Launches New Care Range to Help 14.5 Million People in the UK Suffering Hair Loss Naturally

Retrieved on: 
Tuesday, July 7, 2020
Organ systems, Human hair, Hair diseases, Integumentary system, Hairdressing, Human hair growth, Hair follicle, Hair loss, Hair, Scalp, Hair care, Draft:Hair Care Tips for Female Marines

Clinical trials on the care range showed that after 90 days, 100% of participants saw an increase in anagen (hair growth stage), after 30 days, 92% saw a reduction in hair loss.

Key Points: 
  • Clinical trials on the care range showed that after 90 days, 100% of participants saw an increase in anagen (hair growth stage), after 30 days, 92% saw a reduction in hair loss.
  • Key Ingredients for men: Grape Seed Extract - provides the defence to combat hair loss, Pine Trunk Extract, Niacin, Vitamin B6, Biotin, Panthothenic, Zinc and Copper.
  • Follicle Hero Shampoo cleanses, nourishes, stimulates, revitalises and strengthens hair starting from the scalp through to the ends.
  • Follicle Hero Conditioner will nourish, strengthen, volumize and revitalise hair starting from the scalp and follicles through the hair shafts down to the ends.

Aclaris Therapeutics Submits Investigational New Drug Application for ATI-1777, a Topical “Soft” JAK1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis

Retrieved on: 
Tuesday, July 7, 2020
RTT, Type I hypersensitivity, Medical specialties, Immunology, Autoimmune diseases, Atopic dermatitis, Janus kinase inhibitor, Organ systems, Dermatitis, Atopy

ATI-1777 is another compound generated from the Aclaris KINectdrug discovery platform, and was specifically developed as a topical soft drug.

Key Points: 
  • ATI-1777 is another compound generated from the Aclaris KINectdrug discovery platform, and was specifically developed as a topical soft drug.
  • Soft JAK inhibitors are designed to provide JAK inhibition at the site of application and be rapidly metabolized in the systemic circulation.
  • If the IND is allowed, Aclaris plans to develop ATI-1777 as a potential treatment for moderate to severe atopic dermatitis.
  • These forward-looking statements include expectations regarding ATI-1777 as a potential treatment for patients with moderate to severe atopic dermatitis and the clinical development of ATI-1777.

Flu-Like Symptoms of the ‘Great Masquerader’ Could Fool You Toward Misdiagnosis of Lyme Disease, Cautions Healthy Directions

Retrieved on: 
Tuesday, July 7, 2020
Neurological disorders, Organ systems, Nervous system, RTT, Motor neuron diseases, Rare diseases, Chronic Lyme disease, Lyme disease, Amyotrophic lateral sclerosis, Neuroborreliosis, Allen Steere

So, unfortunately people often go untreated for years, until the Lyme disease symptoms become debilitating.

Key Points: 
  • So, unfortunately people often go untreated for years, until the Lyme disease symptoms become debilitating.
  • The CDC estimates that more than 300,000 people are diagnosed with Lyme disease each year in the United States.
  • Patients can have symptoms of multiple sclerosis (MS), or worse, amyotrophic lateral sclerosis (ALS), but actually have Lyme disease.
  • Sinatra says its very important to seek out a Lyme disease specialist who can quickly recognize Lyme disease symptoms.

Inspire Medical Systems, Inc. to Report Second Quarter 2020 Financial Results on August 4, 2020

Retrieved on: 
Tuesday, July 7, 2020
Sleep disorders, Branches of biology, Sleep apnea, Obstructive sleep apnea, New York Stock Exchange, Organ systems

MINNEAPOLIS, July 07, 2020 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today announced that it will release financial results for the second quarter 2020 after the close of trading on Tuesday, August 4.

Key Points: 
  • MINNEAPOLIS, July 07, 2020 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today announced that it will release financial results for the second quarter 2020 after the close of trading on Tuesday, August 4.
  • Inspires management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.
  • Tuesday, August 4th @ 5:00 p.m. Eastern Time:

2019-2026 Osteoporosis Drugs Market by Drug Class, Route of Administration and Region - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 8, 2020
General Health, Pharmaceutical, Health, Drugs, Organ systems, Health, RTT, Osteopathies, Osteoporosis, Ketones, Conjugated estrogens

The major factor that contributes toward the growth of the global osteoporosis drug market includes a rise in the prevalence of osteoporosis.

Key Points: 
  • The major factor that contributes toward the growth of the global osteoporosis drug market includes a rise in the prevalence of osteoporosis.
  • However, the side effects of osteoporosis drugs, and the time-consuming drug approval process restrain the growth of the global osteoporosis drugs market.
  • The osteoporosis drugs market size is studied on the basis of drug class, route of administration, and region to provide a detailed assessment of the market.
  • By route of administration, the oral segment acquired for the major share of the osteoporosis drugs market owing to a large number of osteoporosis medications that are available as oral drugs in the market.